B.Riley analyst Mayank Mamtani reiterated a Buy rating and $10.00 price target on Opus Genetics (NASDAQ: IRD).The analyst comments "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'July 6, 2026 12:06 PM BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'July 6, 2026 12:06 PM